Brain cancer trial tests common antiviral drug to extend survival
NCT ID NCT04116411
Summary
This study is testing whether adding the antiviral drug valganciclovir to standard glioblastoma treatment helps patients live longer. It involves 220 adults with newly diagnosed glioblastoma who will receive either the antiviral or a placebo alongside their standard chemotherapy and radiation. The goal is to see if targeting a common virus found in these tumors can slow the cancer's progression and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oslo University Hospital
Oslo, Norway
-
SE01 Karolinska University Hospital
Solna, Stockholm County, SE17164, Sweden
-
Stavanger University Hospital
Stavanger, Norway
Conditions
Explore the condition pages connected to this study.